Natera Scores Rare FDA Approval but Shares Drop
Natera shares fell 5.36% to $186.36 Friday despite FDA approval of its Signatera CDx test as a companion diagnostic for Genentech’s Tecentriq in muscle-invasive bladder cancer. The Nasdaq dropped 1.54%. The FDA cited trial results showing improved survival for patients using the test. Regular Nasdaq trading resumes Monday.